Table 1.
Parameters and comparison between prostate biopsy histopathologic results.
| Characteristics | Overall patient's summary (n = 552) | High risk PCa (n = 82) | Intermediate risk PCa (n = 66) | Low risk PCa (n = 48) | BPH (n = 191) | Prostatitis (n = 165) | p-Value |
|---|---|---|---|---|---|---|---|
| Age (year) a | 63.20 ± 8.23 | 68.0 ± 9.30 | 67.0 ± 7.72 | 62.0 ± 6.84 | 60.7 ± 7.06 | 62.0 ± 7.63 | <0.001 |
| BMI a | 25.80 ± 4.06 | 24.6 ± 4.57 | 25.8 ± 3.37 | 26.2 ± 3.96 | 26.2 ± 4.18 | 26.0 ± 4.31 | 0.038 |
| PSA levels (ng/mL) a | 9.38 ± 5.62 | 13.9 ± 6.75 | 11.4 ± 6.22 | 9.2 ± 4.30 | 7.5 ± 4.60 | 8.0 ± 4.43 | <0.001 |
| Prostate gland size by TRUS (g) a | 44.93 ± 18.60 | 44.3 ± 19.13 | 40.2 ± 17.56 | 44.8 ± 13.94 | 45.6 ± 18.02 | 45.8 ± 20.23 | 0.137 |
| PSAD a | 0.24 ± 0.18 | 0.4 ± 0.21 | 0.3 ± 0.22 | 0.2 ± 0.14 | 0.2 ± 0.15 | 0.2 ± 0.16 | <0.001 |
| PSA velocity a | 1.43 ± 1.32 | 2.8 ± 1.01 | 1.8 ± 0.88 | 1.4 ± 0.90 | 0.8 ± 0.70 | 1.3 ± 1.79 | <0.001 |
| Abnormal age specific PSA b | 379 (69) | 78 (95) | 54 (82) | 39 (81) | 100 (52) | 142 (86) | <0.001 |
| With family history of PCa b | 189 (34) | 69 (84) | 25 (38) | 14 (29) | 50 (26) | 53 (32) | <0.001 |
| With hypertension b | 282 (52) | 40 (49) | 32 (48) | 27 (56) | 95 (50) | 104 (63) | 0.830 |
| With diabetes mellitus b | 117 (21) | 16 (20) | 18 (27) | 12 (25) | 39 (20) | 50 (30) | 0.522 |
| Smoker b | 111 (20) | 15 (18) | 14 (21) | 9 (19) | 36 (19) | 48 (29) | 0.958 |
| Alcoholic beverage drinker b | 135 (25) | 18 (22) | 15 (23) | 11 (23) | 58 (30) | 45 (27) | 0.877 |
| With prior antibiotic drinker b | 133 (24) | 19 (23) | 13 (20) | 17 (35) | 61 (32) | 30 (18) | 0.246 |
| Abnormal digital rectal exam b | 103 (19) | 57 (70) | 18 (27) | 6 (13) | 13 (7) | 16 (10) | <0.001 |
| Heterogenic echogenecity on TRUS b | 151 (27) | 33 (40) | 11 (17) | 13 (27) | 24 (13) | 104 (63) | 0.013 |
Notes: aScale variables, values presented as mean ± SD; bCategorical variables, values presented as n(%).
PCa, prostate cancer; BMI, body mass index; PSA, prostate specific antigen; TRUS, transrectal ultrasound; PSAD, PSA density; BPH, benign prostatic hyperplasia.